ICYMI:
Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19 – A double-blind, randomized placebo-controlled trial
https://www.medrxiv.org/content/10.1101/2021.05.31.21258081v1
Abstract
Background Ivermectin, an anti-parasitic agent, also has anti-viral properties. Our aim was to assess whether ivermectin can shorten the viral shedding in patients at an early-stage of COVID-19 infection.
Conclusions There were significantly lower viral loads and viable cultures in the ivermectin group, which could lead to shortening isolation time in these patients.
The study is registered at ClinicalTrials.gov NCT 044297411.
u r doin some heavy lifting...thank you.
Thank you for posting about the trials.